Japan Approves Regeneron and Sanofi's Dupixent for Bullous Pemphigoid Treatment

Japan's Ministry of Health, Labour and Welfare has officially approved Dupixent, developed by Regeneron and Sanofi, for treating adults with moderate-to-severe bullous pemphigoid. The regulatory decision was supported by positive data from the LIBERTY-BP-ADEPT Phase 2/3 clinical trial, which demonstrated the drug's efficacy. This approval marks a significant expansion for Dupixent, further solidifying its role as a primary revenue driver for both pharmaceutical giants. Following the news, Barclays initiated coverage on Regeneron with an Overweight rating and a price target of $923. Analysts believe that the expansion into the Japanese market will provide a substantial boost to the company's long-term growth prospects. The market response remains positive as investors weigh the impact of new indications for blockbuster drugs on corporate valuations.

Sources:Insider Monkeysanofi.comthepharmaletter.comglobenewswire.compharmanow.livenationaltoday.compharmajournalist.commarketscreener.comcheckorphan.org